Abstract
Approximately 10–15% of all myasthenia gravis (MG) patients have a thymoma, and 30 – 60% of all thymoma cases are associated with MG. The clinical manifestations of MG with thymoma are similar to MG with thymic hyperplasia, but the thymoma patients are usually older, and the male:female ratio is about 1:1 compared with 1:2–3 for thymic hyperplasia. Polymyositis and cardiac involvement are uncommon in non-thymoma cases, but are well known in MG with thymoma (Aarli, 1994).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aarli, JA. Myasthenia Gravis and Thymoma. Chapter 10 in: Handbook of Myasthenia Gravis and Myasthenic Syndromes (ed. R. P. Lisak) Marcel Dekker, New York, Pp.207–224, 1994.
Aarli JA, Lefvert AK, Tønder O. Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect hemagglutination. J Neuroimmunol 1981; 1:421–427.
Aarli JA, Gilhus NE, Hofstad H. CA-antibody: an immunological marker of thymus neoplasia in myasthenia gravis? Acta Neurol scand. 1987;76:55–57.
Aarli JA, Stefansson K, Marton LSG, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990; 82:284–288.
Ansevin CF, Agamanolis DP. Rippling muscles and myasthenia gravis with rippling muscles. Arch Neurol 1996; 53:197–199.
Dardenne M, Savino W, Bach JF. Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody. Am J Pathol. 1987; 126:194–198.
Gautel M, Lakey A, Barlow PD, Holmes Z, Scales S, Leonard K, Labeit S, Mygland Å, Gilhus NE, Aarli JA. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin. Neurology 1993; 43:1581–1585.
Geld HW van der and Strauss AJL. Autoantibodies and myasthenia gravis: immunological relationship between striated muscle and thymus. Lancet 1966:i:631–637.
Geuder KI, Marx A, Witzemann V, Schalke B, Kirchner T, Müller-Hermelink. Genomic organization and lack of transcription of the nicotinic acetylcholine receptor subunit genes in myasthenia gravis-associated thymoma. Lab Invest 1992; 66:452–458.
Gilhus N. E., Aarli, J. A., Christensson, B., Matre, R.: Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymoma from myasthenia gravis patients. J. Neuroimmunology 1984; 34:55–64.
Gilhus NE, Aarli JA, Janzen RWC, Otto HF, Fasske E, Matre R. Skeletal muscle antibodies in patients with a thymic tumour but without myasthenia gravis. J Neuroimmunol 1985; 8:69–75.
Gilhus NE, Matre R, Aarli JA, Hofstad H, Thunold S. Thymic lymphoepitheliomas and skeletal muscle expressing common antigen(s). Acta neurol scand 1986; 73:428–433.
Gilhus NE, Willcox N, Harcourt G, Nagvvekar N, Beeson D, Vincent A, Newsom-Davis J. Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells. J Neuroimmunol 1995; 56:65–76.
Hara Y, Ueno S, Uemichi T, Takhashi N, Yorifuji S, Fujii Y, Tarui S. Neoplastic epithelial cells express alpha subunit of muscle nicotinic acetylcholine receptor in thymomas from patients with myasthenia gravis. FEBS letters 1991:279:137–140.
Hassel B, Gilhus NE, Aarli JA, Skogen OR. Fulminant myasthenia gravis and polymyositis after thymectomy for thymoma. Acta neurol scand 1992; 85:63–65.
Kirchner T, Tzartos S, Hoppe F, Schalke B, Wekerle H, Müller-Hermelink HK. Pathogenesis of myasthenia gravis. Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am J Pathol 1988; 130:268–280.
Kornstein MJ, Asher O, Fuchs S. Acetylcholine receptor alpha-subunit and myogenin mRNAs in thymus and thymomas. Am J Pathol 1995; 146:1320–1324.
Kuks JBM. The thymus and myasthenia gravis. Drukkerij Regenboog, Groningen 1992.
Kuks JB, Limburg PC, Horst G, Oosterhuis HJ. Antibodies to skeletal muscle in myasthenia gravis. Part 3. Relation with clinical course and therapy. J Neurol Sci 1993; 120:168–173.
Marx A, Osborn M, Tzartos S, Geuder KI, Schalke B, Nix W, Kirchner T, Müller-Hermelink HK. A striational muscle antigen and myasthenia gravis-associated thymomas share an acetylcholine-receptor epitope. Dev. Immunol. 1992; 2:77–84.
Matsui M, Wada H, Ohta M, Kuroda Y. Potential role of thymoma and other mediastinal tumors in the pathogenesis of myasthenia gravis. J Neuroimmunol 1993; 44:171–176.
Mygland AÅ, Tysnes OB, Aarli JA, Flood PR, Gilhus NE. Myasthenia gravis patients with a thymoma have antibodies against a high molecular weight protein in sarcoplasmic reticulum. J Neuroimmunol 1992; 37:l–7.
Mygland Å, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992; 32:589–591.
Mygland Å, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiat 1994; 57:843–846.
Mygland Å., Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995; 62:79–83.
Osborn M, Marx A, Kirchner T, Tzartos SJ, Plessman U, Weber K. A shared epitope in the acetylcholine receptor alpha subunit and fast troponin I of skeletal muscle. Is it important for myasthenia gravis? Am J Pathol 1992; 140:1215–1223.
Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, Plomp JJ, Van Kempen GTH, Chauplannaz G, Wintzen AR, van Dijk JG, Newsom-Davis J. Acquired neuromyotonia: Evidence of autoantibodies directed against K+−channels of peripheral nerve. Ann Neurol 1995; 38:714–722.
Skeie GO, Mygland Å, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: Clinical correlations. Autoimmunity 1995; 20:99–104.
Somnier FE. Exacerbation of myasthenia gravis after removal of thymoma. Acta Neurol Scand 1994; 90:56–66.
Somnier FE, Trojaburg W. Neurophysiological evaluation in myasthenia gravis. A comprehensive study of a complete patient population. Electroencephalogr Clin Neurophysiol 1993; 89:73–87.
Spurkland A, Gilhus NE, Rønningen KS, Aarli JA, Vartdal F. Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Ant. 1991; 37:90–93.
Strauss AJ, Seegal BC, Hsu JC, Burkholder PM, Nastuk WL, Osserman KE. Immunofluorescence demonstration of a muscle binding, complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol (NY) 1960; 195:184–191.
Weigert C. Patologisch—anatomischhes Beitrag zur Erbschen Krankheit. Neurolog Zentralblatt 1901; 20:594–597.
Wheatley LM, Urso D, Zheng Y, Loh E, Levinson AI. Molecular analysis of intrathymic acetylcholine receptor. Ann NY Acad Sci 1993, 681:74–82.
Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 1992; 66:331–336.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Aarli, J.A. (1997). Clinical Immunology of Thymic Tumors in Patients with Myasthenia Gravis. In: Marx, A., Müller-Hermelink, H.K. (eds) Epithelial Tumors of the Thymus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0033-3_35
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0033-3_35
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0035-7
Online ISBN: 978-1-4899-0033-3
eBook Packages: Springer Book Archive